Rationale for use and clinical responsiveness of hexafluoro-1,25-dihydroxyvitamin D3 for the treatment of plaque psoriasis: a pilot study
Article first published online: 23 DEC 2001
British Journal of Dermatology
Volume 144, Issue 3, pages 500–506, February 2001
How to Cite
Durakovic, C., Malabanan, A. and Holick, M.F. (2001), Rationale for use and clinical responsiveness of hexafluoro-1,25-dihydroxyvitamin D3 for the treatment of plaque psoriasis: a pilot study. British Journal of Dermatology, 144: 500–506. doi: 10.1046/j.1365-2133.2001.04075.x
- Issue published online: 23 DEC 2001
- Article first published online: 23 DEC 2001
- Accepted for publication 15 October 2000
- 25(OH)2D3 ointment;
- psoriasis vulgaris;
- randomized controlled trial
Background Vitamin D analogues are useful in topical therapy of psoriasis.
Objectives To evaluate the effect of hexafluoro-1,25-dihydroxyvitamin D3 (F6-1,25(OH)2D3) in treatment of psoriasis.
Methods Fifteen patients with plaque-type psoriasis were enrolled in a single centre double-blind, right/left comparison, placebo-controlled study, and received 0·1 g of petrolatum containing 5 µg of F6-1,25(OH)2D3 or 0·1 g of petrolatum (placebo) for 3 months. After completion of this double-blind study, a subset of these patients (n = 12) applied F6-1,25(OH)2D3 ointment (50 µg g−1 of petrolatum) to all their lesions (total area, 100–5000 cm2, mean area: 3300 m2) for 2 months as a single application at night.
Results The mean severity score in the right/left-sided controlled topical F6-1,25(OH)2D3 (50 µg g−1) therapy group showed a decrease of 85%. In contrast, the mean severity score for the placebo-treated areas showed a decrease of 45% (P < 0·001). In the 12 patients who subsequently applied F6-1,25(OH)2D3 (50 µg g−1) ointment to all of their lesions, 91·6% showed moderate to excellent improvement. The mean Psoriasis Area and Severity Index score decreased by 44·9% (from 33·6 ± 15 to 18·5 ± 13). No effect on calcium homeostasis was noted. Adverse events included mild irritation in two patients that resolved during therapy.
Conclusions Topical F6-1,25(OH)2D3 is a safe and effective once a day treatment for psoriasis.